Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

ENHANCE : A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naïve Patients With Higher Risk Myelodysplastic Syndrome

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy,Treatment | Blood / Myeloma / LymphomaMyelodysplasia

Trial Overview Read MoreRead more

This phase III trial is testing the addition of a targeted therapy drug to treatment for previously untreated patients with intermediate-very high risk myelodysplastic syndromes (MDS).
 

This trial is treating patients with myelodysplastic syndrome.

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naïve Patients With Higher Risk Myelodysplastic Syndrome

Commercial Sponsor

Gilead Sciences, Inc.

Summary

Eligible patients will be randomised to receive magrolimab or a magrolimab-placebo, with 75mg/m^2 azacitidine administered on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each cycle. Magrolimab will be administered via the following dosing regimens - Cycle 1: 1mg/kg priming dose on Days 1 and 4; 15 mg/kg on Day 8; and 30 mg/kg on Days 11, 15, and 22. Cycle 2: weekly doses of 30 mg/kg on Days 1, 8, 15, and 22. Cycle 3 and onward: 30 mg/kg every 2 weeks on Days 1 and 15.

Recruiting Hospitals Read MoreRead more

Alfred Hospital, Malignant Haematology & Stem Cell Transplantation Service
Prahran
Ms Nola Kennedy
n.kennedy@alfred.org.au
03 9076 2217

Box Hill Hospital, Malignant Haematology
Box Hill
Ms Liz Arnold
liz.arnold@monash.edu
03 9094 9516

Cabrini Education and Research Precinct
Malvern
Li Hoon Lai
lihoonlai@cabrini.com.au
(03) 9508 3421

Monash Health Haematology Research Unit
Clayton
Miss Jeanette Gamgee
jeanette.gamgee@monashhealth.org
03 9594 4044

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Enquiries Line Coordinator
clinicaltrials.enquiries@petermac.org
03 8559 7456 (9am-2pm, Mon-Fri)

Not Recruiting Hospitals Read MoreRead more

Recruitment on hold

Barwon Health, University Hospital Geelong
Geelong
Haematology Team
HaematologyTrials@barwonhealth.org.au

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next